Sinovac Biotech Ltd.

    Sinovac Biotech Ltd.

    NNASDAQ:SVA
    6.47
    USD
    0.00
    (0.00%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    1.3
    1.13
    1.2
    1.27
    3.06
    3.55
    2.59
    5.16
    195.09
    15
    6.55
    5.03
    5.37
    5.16
    Basic EPS, GAAP
    0.13
    -0.03
    -0.03
    -0.01
    0.45
    0.34
    0.42
    1.06
    85.2
    1.08
    -0.27
    1.27
    -0.83
    1.06
    Free Cash Flow per Basic Share
    0.01
    -0.38
    -0.02
    -0.47
    0.84
    0.04
    0.3
    3.56
    147.34
    -11.8
    -0.24
    -2.15
    -7.81
    3.56
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    18.89
    2.64
    4.57
    13.18
    49.18
    - -
    Book Value per Share
    2.32
    2.27
    2.14
    2.03
    2.64
    3.56
    2.97
    7.52
    93.74
    89.66
    121.2
    114.98
    61.77
    7.52
    Tangible Book Value per Share
    2.1
    2.08
    1.97
    1.88
    2.48
    3.45
    2.89
    7.42
    93.33
    88.86
    120.17
    112.03
    59.65
    7.42
    Basic Weighted Avg Shares
    55
    56
    56
    57
    57
    65
    95
    99
    99
    100
    72
    72
    72
    99
    Sales/Revenue/Turnover
    72
    63
    67
    72
    174
    230
    246
    511
    19,375
    1,493
    470
    361
    386
    511
    Operating Margin (%)
    13.98
    3.11
    5.52
    1.36
    26.07
    19.77
    27.98
    42.26
    90.6
    -30.87
    -128.73
    -131.51
    -74.42
    42.26
    Depreciation Expense
    6
    8
    7
    5
    5
    5
    5
    4
    87
    157
    161
    114
    101
    4
    Net Income, GAAP
    7
    -2
    -1
    -1
    26
    22
    45
    110
    8,467
    114
    -13
    91
    -60
    110
    Effective Tax Rate (%)
    - -
    88.12
    108.31
    - -
    18.51
    22.48
    7.91
    14.51
    17.67
    - -
    - -
    5.09
    - -
    14.51
    Profit Margin (%)
    10.37
    -2.41
    -2.1
    -0.82
    14.8
    9.48
    18.26
    21.61
    43.7
    7.63
    -2.87
    25.16
    -15.46
    21.61
    Working Capital
    108
    75
    70
    64
    111
    226
    262
    881
    12,502
    11,035
    10,683
    9,193
    5,524
    881
    LT Debt
    32
    2
    1
    9
    22
    11
    7
    94
    130
    64
    217
    177
    274
    94
    Total Equity
    144
    142
    137
    130
    177
    292
    352
    1,120
    13,876
    12,713
    12,023
    10,293
    6,396
    1,120
    Return on Invested Capital (%)
    - -
    0.12
    -0.17
    - -
    18.72
    13.4
    18.8
    22.18
    174.05
    - -
    - -
    -3.88
    - -
    22.18
    Return on Capital (%)
    - -
    -0.71
    -1.15
    - -
    8.3
    3.17
    7.44
    4.52
    32.45
    - -
    - -
    1.27
    - -
    4.52
    Return on Common Equity (%)
    6.04
    -1.19
    -1.14
    -0.5
    19.34
    10.77
    14.54
    20.06
    167.99
    1.18
    -0.22
    1.07
    -0.94
    20.06

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'20
    Sep'20
    Dec'20
    ST Debt
    22
    37
    43
    LT Borrowings
    16
    23
    8
    LT Finance Leases
    55
    58
    85
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    99
    99
    99
    Market Capitalization
    - -
    - -
    - -

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'20
    Sep'20
    Dec'20
    Total Current Assets
    338
    425
    1,560
    Cash, Cash Equivalents & STI
    177
    184
    1,176
    Accounts Receivable, Net
    106
    170
    251
    Inventories
    46
    57
    106
    Total Current Liabilities
    114
    194
    680
    Payables & Accruals
    83
    136
    258
    ST Debt
    22
    37
    43
    Deferred Revenue
    9
    20
    379

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    140.78%
    214.55%
    -37.86%
    Free Cash Flow
    912.02%
    979.51%
    263.36%
    Net Income, GAAP
    217.04%
    1,284.4%
    -165.65%
    Sales/Revenue/Turnover
    381.18%
    703.45%
    6.82%
    Total Cash Common Dividend
    - -
    -6,156.25%
    273.22%

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    361
    2025
    - -
    - -
    - -
    - -
    386
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    1.27
    2025
    - -
    - -
    - -
    - -
    -0.83
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    13.18
    2025
    - -
    - -
    - -
    - -
    49.18
    2026
    - -
    - -
    - -
    - -
    - -

    Company Description

    Address
    Similar Companies
    Business

    Company News

    • Sernova, Seraxis Aim for Type 1 Diabetes ‘Functional Cure’ With BetaNova Merger

    • SINOVAC Reports Unaudited First Half of 2026 Financial Results

    • SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

    • SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements

    • SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

    • SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

    • SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

    • SINOVAC Reports Unaudited First Half of 2025 Financial Results

    • SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

    • SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

    • SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

    • Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

    • Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

    • SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

    • Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

    • SINOVAC Announces Appointment of Independent Auditor

    • SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    • Newly Elected Directors of Sinovac Hold the First Board Meeting

    • SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

    • SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment